The global non-alcoholic steatohepatitis biomarkers market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing incidence of chronic liver conditions, which has resulted to increase demand for non-invasive diagnostic tools.
The prevalence of non-alcoholic steatohepatitis (NASH) has increased over the recent years and the adoption of NASH biomarkers since it leads to liver failure as a consequence. According to a health report, around 20% patients in the US are suffering from NASH disease and are susceptible to cirrhosis-a condition in which scar tissues replaces healthy tissues and around 10% becomes the victims of the disease. As per a study in 2009 by the United States Census Bureau, around 13% of total US population were represented by people attaining the age of 65 and above older people and the trend is projected to rise up to 20% by 2030.
Nonalcoholic fatty liver disease (NAFLD) is accurately diagnosed by the use of several devices such as magnetic resonance imaging, ultrasound scanning, and computed tomography, which are imaging techniques. However, the adoption of these imaging techniques are not sufficient for NASH detection or liver fibrosis detection. Due to this, it is expected that these factors are responsible for increasing in demand of noninvasive diagnostic tools in the coming years.
Growing initiatives for the development of NASH drugs is one of the factor responsible for NASH biomarkers market growth. In 2016, GENFIT, one of the biopharmaceutical company has launched the NASH Education Program. This program was aimed for generating awareness about NASH among patients. Moreover, the company introduced pediatric NAFLD/NASH Program in Europe by taking approval by elafibranor’s pediatric investigation plan by the European Medicine Agency, which is expected to aid drug development program in the coming years.
The report on the global non-alcoholic steatohepatitis biomarkers market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Non-alcoholic Steatohepatitis Biomarkers Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2020 |
Historic Data |
2018–2019 |
Forecast Period |
2021–2028 |
Segmentation |
Types (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, and Others) and End-users (Pharma & CRO Industry, Hospitals, Diagnostic Labs, and Academic Research Institutes) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
GENFIT Gilead, AstraZeneca, Novartis AG, Bristol-Myers Squibb, Allergan Novo Nordisk A/S, Boehringer Ingelheim GmbH, and Pfizer, Inc. |
Serum biomarkers segment is projected to hold a large market share
Based on types, the non-alcoholic steatohepatitis biomarkers market is divided into serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others. The serum biomarkers segment accounted for a large market share in 2020 and is anticipated to expand at a rapid pace during the forecast period due to its benefits such as efficient outcome and capability to differentiate simple steatosis from NASH. The serum biomarkers are widely used for detecting NASH and the production of new technology to diagnose the level of free fatty acids, apolipoprotein A1, leptin, ghrelin & tumor necrosis factor-alpha, adiponectin and apolipoprotein B are boosting the segment growth. The serum biomarkers are also found in various applications such as diagnosis of ovarian, colorectal, prostate, and lung and breast-related disorders.
However, the hepatic fibrosis biomarkers segment is projected to exhibit a rapid growth rate during the forecast period due to efficiency and high accuracy. The hepatic fibrosis biomarkers are considered to be attractive and affordable alternative for physicians and patients for the diagnosis of diseases.
Pharma & CRO industry segment is expected to grow at a rapid pace
On the basis of end-users, the market is segmented into pharma & CRO industry, hospitals, diagnostic labs, and academic research institutes. The pharma and CROs industry accounted for a major market share in 2019 and is projected to expand at a significant growth rate over the forecast period. Growing demand for noninvasive NASH diagnostic and monitoring tools for clinical trials are responsible for the segment growth. Many companies are doing research on NASH therapeutics. Some factors such as high cost of treatment, complex pathophysiology, and unknown etiology are projected to restrain the revenue growth of this segment.
A noninvasive technique is preferred during clinical trials for routine monitoring of drug therapy, which is anticipated to fuel the growth of hospitals and diagnostics segment. After the drug launch in hospitals and diagnostic laboratories, the use of biomarkers are widely practices, which is projected to grow the segment growth. Hence, the hospitals and diagnostic laboratories segment is projected to show rapid growth over the forecast period.
North America is expected to dominate the market
In terms of regions, the non-alcoholic steatohepatitis biomarkers market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to expand at an impressive CAGR during the forecast period. In North America, these factors such as wide prevalence of cardiovascular diseases, favorable government initiatives, cancer and increasing occurrence of infectious diseases are responsible for the regional market growth. The drug development activities are supported by key players with allocating a large funding for research and development for the production of innovative biomarkers, which are expected to propel the regional market growth.
The market in Asia Pacific is anticipated to constitute a large market share in the coming years owing to the rising expansion of several diagnostics centers and clinical labs due to rising spending on research and development. The players based in countries such as China and Japan are increasing their spending on R&D, which leads to market growth. The US and European companies are willing to invest in Asia Pacific because of factors such as cheaper clinical trials and immense target population. This is projected to propel the regional market growth.
Segments Covered in the Report
The global non-alcoholic steatohepatitis biomarkers market has been segmented on the basis of
Types
End-users
Regions
Key Players
Key players competing in the non-alcoholic steatohepatitis biomarkers market include GENFIT Gilead, AstraZeneca, Novartis AG, Bristol-Myers Squibb, Allergan Novo Nordisk A/S, Boehringer Ingelheim GmbH, and Pfizer, Inc.
Some of these players are implementing several business strategies including mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. Existing market players, having less diversified product portfolio, are competing with new players to enter with their diversified and innovative product portfolios. Moreover, new players enter in the market due to growing demand of accurate and efficient diagnostics.
Some other reports from this category!